NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics) ネクタ―・セラピュ―ティクス

 NKTRのチャート


 NKTRの企業情報

symbol NKTR
会社名 Nektar Therapeutics (ネクタ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ネクター・セラピューティクス(Nektar Therapeutics)は医薬品を発見・開発するバイオ医薬品企業である。同社の新規治験薬の研究開発パイプラインには、がん、自己免疫疾患、慢性疼痛の治療が含まれる。同社は化学物質のプラットフォームを活用して新薬の候補を発見・設計する。薬物候補は既知の作用機序を標的とする新しい分子実体の開発を可能にするように設計されたポリマーコンジュゲート技術プラットフォームを利用する。同社のプログラムには、免疫腫瘍学(I-O)、免疫学、Pain-NKTR-181、および腫瘍学ONZEALDが含まれる。同社は細胞傷害性T細胞やナチュラルキラー(NK)細胞などの主要な免疫細胞の活性を直接的または間接的に調節してその数を増やし、癌細胞を認識して攻撃する機能を改善するように設計された医薬品を開発する。   ネクタ―・セラピュ―ティクスは、米国の医薬品開発会社。PEG化と高度なポリマ―接合体技術プラットフォ―ムを利用し、薬剤を開発。同社の薬剤候補ナロキセゴ―ルは、オピオイド誘発性便秘の治療に使われる経口末梢性オピオイド拮抗薬で、非癌性疼痛をもつ患者に使われる。その他、「Etirinotecanペゴル」、「NKTR-181」などがある。   Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
本社所在地 455 Mission Bay Boulevard South San Francisco CA 94158 USA
代表者氏名 Robert B. Chess ロバートB.チェス
代表者役職名 Independent Chairman of the Board
電話番号 +1 415-482-5300
設立年月日 33055
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 509人
url www.nektar.com
nasdaq_url https://www.nasdaq.com/symbol/nktr
adr_tso
EBITDA EBITDA(百万ドル) 959.86200
終値(lastsale) 51.79
時価総額(marketcap) 8932157753.67
時価総額 時価総額(百万ドル) 8261.254
売上高 売上高(百万ドル) 1374.129
企業価値(EV) 企業価値(EV)(百万ドル) 6683.524
当期純利益 当期純利益(百万ドル) 902.71300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nektar Therapeutics revenues increased from $59.3M to $1.13B. Net income totaled $875.7M vs. loss of $123.7M. Revenues reflect License collaboration and other increase from $10.9M to $1.08B Royalty revenue increase of 34% to $19.6M Non-cash royalty revenue related to sale increase of 20% to $16M. Net Income reflects Other income (expense) net increase from $1.6M to $13.7M (income).

 NKTRのテクニカル分析


 NKTRのニュース

   The Case for a Bear Market Rally: Analysts Upgrade or Downgrade Dow, Rocket Companies, Zoom Video and More  2022/05/31 15:35:34 24/7 Wall street
Tuesday’s additional top analyst upgrades and downgrades included Dow, Estee Lauder, Magellan Midstream Partners, Nektar Therapeutics, Novo Nordisk, Rocket Companies, Sherwin-Williams, Steel Dynamics and Zoom Video Communications.
   Weak Fundamental Momentum Sinks Nektar Therapeutics  2022/05/17 14:30:00 Marketing Sentinel
Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 1.35 and has seen 2.94 million shares traded in the last trading session. The company, currently valued at $675.66M, closed the last trade at $3.88 per share which meant it lost -$0.11 on the day or -2.76% during that session. The NKTR stock price is -399.23% off … Weak Fundamental Momentum Sinks Nektar Therapeutics Read More »
   Nektar Therapeutics GAAP EPS of -$0.49 beats by $0.21, revenue of $24.8M misses by $0.09M  2022/05/05 20:49:37 Seeking Alpha
Nektar Therapeutics press release (NKTR): Q1 GAAP EPS of -$0.49 beats by $0.21.Revenue of $24.8M (+4.9% Y/Y) misses by $0.09M.Cash and investments in marketable securities at March…
   Nektar Therapeutics Reports First Quarter 2022 Financial Results  2022/05/05 20:15:00 PR Newswire
SAN FRANCISCO, May 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at…
   The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More  2022/05/02 12:26:53 Benzinga
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks during the week. Molecular Partners AG (MOLN) was among the worst decliners of the week, reacting to potential issues with the emergency use authorization filing for its antiviral candidate and a loss of partnership with Amgen, Inc. (NASDAQ: AMGN ). On the other hand, Nektar Therapeutics (NASDAQ: NKTR ) and Vaxxinity, Inc. (NASDAQ: VAXX ) advanced strongly, with the former reacting to its reorganization and the latter to an update on its early-stage Parkinson''s disease trials. Here are the key catalysts scheduled for the unfolding week: Conferences Pediatric Endocrine Society, or PES, 2022 Annual Meeting: April 28-May 1 (virtual) 14th European Paediatric Neurology Society, or EPNS, Congress: April 28-May 2, in Glasgow, U.K. 13th European and Global CLINAM Summit for Nanomedicine: May 2-4 (virtual) ESMO''s Breast Cancer Congress 2022: May 3-5, in Berlin, Germany Association for Research in Vision and Ophthalmology, or ARVO, 2022: May 1-4, in Denver, Colorado and virtually 2022 Synthetic Biology: Engineering, Evolution & Design (SEED): May 2-5, in Arlington, Virginia The American Society of Interventional Pain Physicians, or ASIPP, 24th Annual Meeting: May 5-7, in Caesars Place, in Las Vegas Genetic Metabolic Dieticians International, or GMDI, Conference: May 5-7 PDUFA Dates The Food and Drug Administration is scheduled to rule on Phathom Pharmaceuticals, Inc.''s (NASDAQ: PHAT ) new drug applications for two vonoprazan combinations for treating Helicobacter pylori infection in adults.
   Nektar Therapeutics'' (NKTR) CEO Howard Robin on Q4 2021 Results - Earnings Call Transcript  2022/03/01 01:07:11 Seeking Alpha
   Nektar Therapeutics GAAP EPS of -$0.79 beats by $0.02, revenue of $25M misses by $0.33M  2022/02/28 21:21:55 Seeking Alpha
Nektar Therapeutics press release (NKTR): Q4 GAAP EPS of -$0.79 beats by $0.02.Revenue of $25M (+6.6% Y/Y) misses by $0.33M.Shares -0.88%.Cash and investments in marketable…
   Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results  2022/02/28 21:15:00 PR Newswire
SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and investments in marketable securities at December 31, 2021 were approximately $0.8 billion as compared to…
   Nektar Therapeutics Q4 2021 Earnings Preview (NASDAQ:NKTR)  2022/02/27 22:35:00 Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.80 and the consensus…
   Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight  2022/02/21 18:00:00 Benzinga
Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Toll-Like Receptor Agonist treatment scenario include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and many others.
   Morgan Stanley Sells 42,117 Shares of Nektar Therapeutics (NASDAQ:NKTR)  2021/12/01 09:34:45 Dakota Financial News
Morgan Stanley reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,014 shares of the biopharmaceutical companys stock after selling 42,117 shares during the quarter. Morgan Stanley owned 0.26% of Nektar Therapeutics []
   Brokerages Expect Nektar Therapeutics (NASDAQ:NKTR) to Announce -$0.82 Earnings Per Share  2021/12/01 04:18:46 Dakota Financial News
Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce ($0.82) earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Nektar Therapeutics earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.89). Nektar Therapeutics posted earnings of ($0.65) per share during the same quarter last year, []
   Thinking About Buying Nektar Therapeutics Stock? Heres What You Need To Know.  2021/11/26 13:00:00 Stocks Register
Nektar Therapeutics (NASDAQ:NKTR) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.84% to the previous days close as strong demand from buyers drove the stock to $11.62. Actively observing the price movement in the last trading, the stock closed the session at $11.41, falling within a range of $11.09 and Thinking About Buying Nektar Therapeutics Stock? Heres What You Need To Know. Read More »
   33,724 Shares in Nektar Therapeutics (NASDAQ:NKTR) Purchased by Marshall Wace North America L.P.  2021/11/24 11:42:41 Transcript Daily
Marshall Wace North America L.P. bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 33,724 shares of the biopharmaceutical companys stock, valued at approximately $579,000. A number of other large investors also recently modified their []
   Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CFO Sells $38,070.00 in Stock  2021/11/21 11:38:41 Dakota Financial News
Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,000 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $12.69, for a total value of $38,070.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ネクタ―・セラピュ―ティクス NKTR Nektar Therapeutics)

 twitter  (公式ツイッターやCEOツイッターなど)